Top > Search of International Patents > NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE.

NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE.

Foreign code F160008799
File No. (S2014-1273-N0)
Posted date Aug 4, 2016
Country WIPO
International application number 2015JP004928
International publication number WO 2016051767
Date of international filing Sep 29, 2015
Date of international publication Apr 7, 2016
Priority data
  • 62/057,632P (Sep 30, 2014) US
Title NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE.
Abstract Alternative menaquinone biosynthetic pathway via futalosine or 6-aminodeoxyfutalosine as an intermediate (futalosine pathway) is an attractive target for new narrow-spectrum antimicrobial agents. Siamycin I and fatty acids were provided as selective antimicrobial activity against bacteria such as Helicobacter and Campylobacter, which depend on the futalosine pathway to grow. Specifically, siamycin I and omega-3 polyunsaturated fatty acids inhibited the colonization of H. pylori in vivo and thus siamycin I and omega-3 polyunsaturated fatty acids could be a new narrow-spectrum antibiotic for Helicobacter and Campylobacter
Scope of claims [claim1]
1. Siamycin I or a fatty acid for the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway in the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject.
[claim2]
2. Siamycin I or a fatty acid for inhibiting synthesis of menaquinone through the futalosine pathway by a bacterium in a subject who is infected by the bacterium comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway.
[claim3]
3. The Siamycin I or a fatty acid of claim 1 or 2, wherein the bacterium is selected from a group consisting of genus of Helicobacter, Campylobacter, Wolinella and Streptomyces.
[claim4]
4. The Siamycin I or a fatty acid of claim 1 or 2, wherein the bacterium is a Helicobacter pylori,
[claim5]
5. The Siamycin I or a fatty acid of claim 1 or 2, wherein the fatty acid is at least one fatty acid that is selected from a group consisting of omega-3 fatty acids, α-linolenic acid, EPA, DHA, oleic acid, linoleic acid, and arachidonic acid.
[claim6]
6. A method for the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway.
[claim7]
7. A method for inhibiting synthesis of menaquinone through the futalosine pathway by a bacterium in a subject who is infected by the bacterium, comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway.
[claim8]
8. A pharmaceutical composition comprising siamycin I or a fatty acid for use in treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid inhibits the futalosine pathway in the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject.
[claim9]
9. A pharmaceutical composition comprising siamycin I or a fatty acid for use in inhibiting synthesis of menaquinone through the futalosine pathway by bacterium in a subject who is infected by the bacterium comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid can inhibit the futalosine pathway.
[claim10]
10. A method for the prevention of bacterium propagation in food, feedstuff or drinking water that contain siamycin I or a fatty acid.
[claim11]
11. The method of claim 10, wherein feedstuff or drinking water application in combating Campylobacter propagation in poultry.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • THE KITASATO INSTITUTE
  • Inventor
  • OMURA SATOSHI
  • MATSUI HIDENORI
  • NAKANO HIROFUMI
  • YAMAMOTO TSUYOSHI
  • YAMAJI KENZABURO
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close